Angiodynamics vs Staar Surgical
Angiodynamics is the larger business, with $320m of revenue in fiscal 2026 against $239m for Staar Surgical (1.3 times as much). Angiodynamics grew faster (9.5% against -23.7%). Angiodynamics kept more of each dollar of sales as profit: a net margin of -11.5% against -33.6%. Angiodynamics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | AngiodynamicsANGO, 2026 | Staar SurgicalSTAA, 2025 |
|---|---|---|
| Revenue | $320m | $239m |
| Revenue growth | 9.5% | -23.7% |
| Net income | −$36.7m | −$80.4m |
| Operating margin | -12.5% | -38.3% |
| Net margin | -11.5% | -33.6% |
| Return on equity | -20.8% | -21.7% |
| Free cash flow | $508,000 | −$40.0m |
| Cash | $53.9m | $153m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $0 | $6.5m |
| Employees | 632 | 957 |
| Market value | $499m | $1.25bn |
| Price vs our value range | — | — |
| Moat score | 53 (Moderate) | 34 (Weak) |
| Insider trades, 12 months | 0 buys, 3 sales | 21 buys, 0 sales |